Document is current
Any future updates will be listed below
-
Authors
Russell, Callan D.
Daley, Ashley V.
Van Arnem, Durand R.
Hila, Andi V.
Johnson, Kiley J.
Davies, Jill N.
Cytron, Hanah S.
Ready, Kaylene J.
Armstrong, Cary M.
Sylvester, Mark E.
Caleshu, Colleen A.
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 17 October 2024
First Online: 8 November 2024
Declarations
:
: The WIRB-Copernicus Group Institutional Review Board performed an expedited review and deemed the study exempt research under 45 CFR ยงย 46.104(d)(4) and approved a waiver of authorization for use and disclosure of protected health information (PHI) because the study analyzed deidentified secondary data.
: Not applicable.
: CR, AD, DV, AH, KJ, JD, HC, CA, MS, CC declare employment at Genome Medical; AD, DV, AH, KJ, JD, HC, CA, MS, CC declare stock and/or stock options in Genome Medical; KJ, JD, MS declare leadership in Genome Medical; CR, AD, DV, AH, KJ, JD, KR, CA, MS, CC declare a patent pending on technology underpinning the digital tool that is the focus of this article; KR declares stock options in Stata Oncology; DV declares employment, ownership interest, and consulting with Call Light Health.
